NTRB实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	8 747.00
平均成交量	46 685.00
市值	27.34M
EPS	$0 ( 2024-04-24 )
下一个收益日期	( $0 ) 2024-06-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.21
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-09	Goodman Gerald	Buy	20 000	Stock Option
2022-08-16	Goodman Gerald	Buy	23 333	Stock Option
2022-01-21	Goodman Gerald	Buy	11 167	Stock Option
2021-10-22	Goodman Gerald	Buy	87 500	CS Purchase Warrant
2023-10-27	Goodman Gerald	Buy	49 500	Stock Option

INSIDER POWER
90.09
Last 21 transactions
Buy: 293 666 \| Sell: 1 500 500

Nutriband Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nutriband Inc. 财务报表

Annual	2023
营收:	$2.09M
毛利润:	$818 893 (39.27 %)
EPS:	$-0.690

FY	2023
营收:	$2.09M
毛利润:	$818 893 (39.27 %)
EPS:	$-0.690

FY	2022
营收:	$2.08M
毛利润:	$750 409 (36.08 %)
EPS:	$-0.570

FY	2022
营收:	$1.42M
毛利润:	$504 310 (35.46 %)
EPS:	$-1.060

Financial Reports:

No articles found.

Nutriband Inc.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.